异动解读|阿尔尼拉姆制药公司盘后上涨5.54%,Amvuttra政策担忧缓和带动反弹

行情直击
Nov 05

11月5日,阿尔尼拉姆制药公司盘后上涨5.54%,报170.0美元/股,成交额979.55万美元。

消息面上,市场围绕核心产品Amvuttra的340B报销政策不确定性与三季度指引偏保守持续交易,在前期连续回调后,政策担忧阶段性缓和,推动股价反弹。

公司此前披露三季度营收14.58亿美元,高于市场预期的14.34亿美元,并维持全年净产品收入47亿至51亿美元区间。机构观点显示,Amvuttra当季销售大体符合预期,尽管TTR收入预期偏向指引下沿,但公司基本面仍被认为稳健,前期跌幅或已部分反映利空。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10